Compare JD.Com Inc (JD) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Medpace Holdings Inc — how do they compare? JD.Com Inc trades at $30.23 (market cap $41.80B), while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: JD.Com Inc is far larger — about 2.8× Medpace Holdings Inc's market cap, and JD.Com Inc pays a 3.27% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| JD | MEDP | |
|---|---|---|
Market Cap | $41.80B | $15.08B |
Sector | Consumer Cyclical | Technology |
52-Week High | $36.17 | $620.59 |
52-Week Low | $25.19 | $308.88 |
Enterprise Value | $27.96B | $14.55B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $30.43, up 2.73% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q1 2026 EPS of $0.74 exceeding expectations. Revenue reached $1.31 trillion in 2025, though net margins compressed to 1.05%. Technical indicators signal bullish momentum with the stock trading near key resistance levels.
Wall Street maintains strong bullish outlook with 69.6% buy ratings and $39.50 consensus target, representing 30% upside potential. Key risks include margin pressure, regulatory investigations, and Chinese market volatility. The company's aggressive buyback program and AI investments provide fundamental support despite competitive pressures.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
